Literature DB >> 12070925

[Treatment protocol for cervical carcinoma].

Tamara Vujkov1, Milica Zivaljević, Petar Novaković, Marko Erak, Jelka Rajović, Aljosa Mandić.   

Abstract

INTRODUCTION: Cervical cancer is the second most common cancer in women worldwide and the second cause of cancer death among women. About 95% (90% in developed countries) of invasive carcinomas are of squamous types, and 5% (10% in developed countries) are adenocarcinomas. FIGO classification of cervical carcinomas, based on clinical staging and prognostic factor dictate therapeutic procedures and help in designing treatment protocols. THERAPEUTIC MODALITIES: Surgical therapy includes conization, radical hysterectomy with pelvic lymphadenectomy and palliative operation--urinary diversion and colostomy. Radiotherapy, brachytherapy and teletherapy are most recently combined with chemotherapy as concurrent chemoradiation. DISCUSSION AND
CONCLUSION: No change in therapeutic modalities will ever decrease mortality rate of cervical carcinoma as much as education, prevention and early screening. The 5-year survival for locally advanced disease has not improved during the last 40 years as a result of failure to deliver therapy to the paraaortic region. Paraaortic lymph nodes should be evaluated before therapy planning by different imaging procedures, or more exactly by surgical staging: laparoscopy or laparotomy. Radical operations of cervical carcinoma should be performed by experienced surgeons, educated for this type of operation, with sufficient number of cases.

Entities:  

Mesh:

Year:  2002        PMID: 12070925     DOI: 10.2298/mpns0204105v

Source DB:  PubMed          Journal:  Med Pregl        ISSN: 0025-8105


  1 in total

1.  High expression of TGF-β1 in the vaginal incisional margin predicts poor prognosis in patients with stage Ib-IIa cervical squamous cell carcinoma.

Authors:  Dong-Mei Fan; Xin-Jun Wang; Tao He; Yan Wang; Dan Zhou; Guo-Qiang Kong; Tao Jiang; Mei-Mei Zhang
Journal:  Mol Biol Rep       Date:  2011-07-20       Impact factor: 2.316

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.